Physician profile
Robert Goodwin Person
NPI 1740294305
$8,814.99
in general payments reported to CMS, 2019-2025
36 companies · $551 in 2025
The $551 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $1,491 · 2021: $2,387 · 2022: $1,378 · 2023: $825 · 2024: $1,246 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,622.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,131.77 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $949.04 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $829.55 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $631.67 | 2021-2025 | |
| Lilly USA, LLC | $631.44 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $617.79 | 2019-2024 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $432.40 | 2019-2023 | Synjardy, Tradjenta |
| Amgen INC. | $423.35 | 2019-2024 | Otezla, Repatha, Krystexxa |
| Pfizer INC. | $411.52 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $353.02 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $303.82 | 2019-2022 | |
| Allergan, INC. | $219.71 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $218.72 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $176.92 | 2021-2024 | |
| Exact Sciences Corporation | $131.96 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $129.53 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $109.48 | 2019-2021 | |
| Dexcom, INC. | $108.70 | 2021-2022 | |
| Stryker Corporation | $102.03 | 2021 | |
| Boston Scientific Corporation | $97.34 | 2020-2021 | |
| Abbott Laboratories | $84.94 | 2021-2022 | |
| Daiichi Sankyo INC. | $84.60 | 2020-2023 | Injectafer |
| Esperion Therapeutics, INC. | $83.14 | 2020-2025 | Nexletol |
| Astellas Pharma US INC | $79.39 | 2019-2023 | Veozah |
| Xeris Pharmaceuticals, INC. | $73.09 | 2023-2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.24 | 2019-2023 | Xifaxan |
| Eisai INC. | $64.77 | 2021-2024 | |
| Mylan Specialty L.P. | $57.45 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $46.41 | 2021-2024 | Rexulti |
| Edwards Lifesciences Corporation | $41.42 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Idorsia Pharmaceuticals US INC | $34.17 | 2022-2024 | Quviviq |
| Lucid Diagnostics INC. | $20.44 | 2024 | |
| Amarin Pharma, INC. | $19.73 | 2021 | |
| Smith+Nephew, INC. | $18.07 | 2023 | Tandem, Polarstem, Or3o Dual Mobility |
| Hikma Pharmaceuticals USA | $15.56 | 2021 | |
| Genentech USA, INC. | $14.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Person listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.